- Home
- ATCH vs SLRX Comparison
ATCH vs SLRX Comparison
Compare ATCH & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- SLRX
- Stock Information
- Founded
- ATCH 2022
- SLRX N/A
- Country
- ATCH United States
- SLRX United States
- Employees
- ATCH N/A
- SLRX N/A
- Industry
- ATCH
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- SLRX Health Care
- Exchange
- ATCH Nasdaq
- SLRX Nasdaq
- Market Cap
- ATCH 2.5M
- SLRX 2.1M
- IPO Year
- ATCH N/A
- SLRX N/A
- Fundamental
- Price
- ATCH $2.35
- SLRX $1.34
- Analyst Decision
- ATCH
- SLRX
- Analyst Count
- ATCH 0
- SLRX 0
- Target Price
- ATCH N/A
- SLRX N/A
- AVG Volume (30 Days)
- ATCH 250.1K
- SLRX 71.1K
- Earning Date
- ATCH 02-19-2025
- SLRX 03-21-2025
- Dividend Yield
- ATCH N/A
- SLRX N/A
- EPS Growth
- ATCH N/A
- SLRX N/A
- EPS
- ATCH 2.67
- SLRX N/A
- Revenue
- ATCH N/A
- SLRX N/A
- Revenue This Year
- ATCH N/A
- SLRX N/A
- Revenue Next Year
- ATCH N/A
- SLRX N/A
- P/E Ratio
- ATCH $0.88
- SLRX N/A
- Revenue Growth
- ATCH N/A
- SLRX N/A
- 52 Week Low
- ATCH $1.73
- SLRX $1.22
- 52 Week High
- ATCH $209.40
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- ATCH 23.48
- SLRX 32.32
- Support Level
- ATCH $1.73
- SLRX $2.08
- Resistance Level
- ATCH $2.40
- SLRX $1.94
- Average True Range (ATR)
- ATCH 0.60
- SLRX 0.14
- MACD
- ATCH 0.07
- SLRX -0.09
- Stochastic Oscillator
- ATCH 20.53
- SLRX 2.80
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.